Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TBK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TBK1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TBK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:004312318 | Esophagus | ESCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 132/8552 | 186/18723 | 2.07e-12 | 8.58e-11 | 132 |
GO:0043122110 | Esophagus | ESCC | regulation of I-kappaB kinase/NF-kappaB signaling | 167/8552 | 249/18723 | 6.11e-12 | 2.32e-10 | 167 |
GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
GO:001624114 | Esophagus | ESCC | regulation of macroautophagy | 102/8552 | 141/18723 | 1.09e-10 | 3.27e-09 | 102 |
GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:003434013 | Esophagus | ESCC | response to type I interferon | 48/8552 | 58/18723 | 6.18e-09 | 1.26e-07 | 48 |
GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
GO:00603375 | Esophagus | ESCC | type I interferon signaling pathway | 41/8552 | 50/18723 | 1.35e-07 | 2.17e-06 | 41 |
GO:00713575 | Esophagus | ESCC | cellular response to type I interferon | 42/8552 | 52/18723 | 2.15e-07 | 3.30e-06 | 42 |
GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
GO:00607595 | Esophagus | ESCC | regulation of response to cytokine stimulus | 103/8552 | 162/18723 | 3.14e-06 | 3.53e-05 | 103 |
GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
GO:1901214111 | Esophagus | ESCC | regulation of neuron death | 186/8552 | 319/18723 | 3.35e-06 | 3.73e-05 | 186 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501462 | Oral cavity | NEOLP | Amyotrophic lateral sclerosis | 95/1112 | 364/8465 | 8.76e-12 | 3.98e-10 | 2.50e-10 | 95 |
hsa0502262 | Oral cavity | NEOLP | Pathways of neurodegeneration - multiple diseases | 112/1112 | 476/8465 | 1.33e-10 | 3.84e-09 | 2.41e-09 | 112 |
hsa0516762 | Oral cavity | NEOLP | Kaposi sarcoma-associated herpesvirus infection | 56/1112 | 194/8465 | 4.05e-09 | 9.20e-08 | 5.78e-08 | 56 |
hsa0513163 | Oral cavity | NEOLP | Shigellosis | 62/1112 | 247/8465 | 1.93e-07 | 2.79e-06 | 1.75e-06 | 62 |
hsa0413762 | Oral cavity | NEOLP | Mitophagy - animal | 26/1112 | 72/8465 | 5.95e-07 | 7.88e-06 | 4.95e-06 | 26 |
hsa0516061 | Oral cavity | NEOLP | Hepatitis C | 43/1112 | 157/8465 | 1.26e-06 | 1.34e-05 | 8.43e-06 | 43 |
hsa0516961 | Oral cavity | NEOLP | Epstein-Barr virus infection | 51/1112 | 202/8465 | 1.96e-06 | 2.01e-05 | 1.27e-05 | 51 |
hsa0516361 | Oral cavity | NEOLP | Human cytomegalovirus infection | 55/1112 | 225/8465 | 2.32e-06 | 2.30e-05 | 1.45e-05 | 55 |
hsa0516461 | Oral cavity | NEOLP | Influenza A | 43/1112 | 171/8465 | 1.38e-05 | 1.22e-04 | 7.68e-05 | 43 |
hsa0517061 | Oral cavity | NEOLP | Human immunodeficiency virus 1 infection | 49/1112 | 212/8465 | 4.05e-05 | 3.22e-04 | 2.02e-04 | 49 |
hsa051626 | Oral cavity | NEOLP | Measles | 35/1112 | 139/8465 | 8.30e-05 | 6.14e-04 | 3.86e-04 | 35 |
hsa0541763 | Oral cavity | NEOLP | Lipid and atherosclerosis | 47/1112 | 215/8465 | 2.39e-04 | 1.61e-03 | 1.01e-03 | 47 |
hsa0513561 | Oral cavity | NEOLP | Yersinia infection | 33/1112 | 137/8465 | 3.20e-04 | 2.00e-03 | 1.26e-03 | 33 |
hsa051616 | Oral cavity | NEOLP | Hepatitis B | 37/1112 | 162/8465 | 4.41e-04 | 2.60e-03 | 1.63e-03 | 37 |
hsa0414061 | Oral cavity | NEOLP | Autophagy - animal | 32/1112 | 141/8465 | 1.17e-03 | 5.56e-03 | 3.49e-03 | 32 |
hsa046216 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
hsa0465761 | Oral cavity | NEOLP | IL-17 signaling pathway | 22/1112 | 94/8465 | 4.40e-03 | 1.75e-02 | 1.10e-02 | 22 |
hsa0517174 | Oral cavity | NEOLP | Coronavirus disease - COVID-19 | 112/1112 | 232/8465 | 8.85e-40 | 2.82e-37 | 1.77e-37 | 112 |
hsa0516571 | Oral cavity | NEOLP | Human papillomavirus infection | 90/1112 | 331/8465 | 2.75e-12 | 1.75e-10 | 1.10e-10 | 90 |
hsa0501472 | Oral cavity | NEOLP | Amyotrophic lateral sclerosis | 95/1112 | 364/8465 | 8.76e-12 | 3.98e-10 | 2.50e-10 | 95 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TBK1 | SNV | Missense_Mutation | novel | c.1664N>A | p.Leu555Gln | p.L555Q | Q9UHD2 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
TBK1 | SNV | Missense_Mutation | | c.81A>T | p.Arg27Ser | p.R27S | Q9UHD2 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TBK1 | SNV | Missense_Mutation | novel | c.1136N>C | p.Ile379Thr | p.I379T | Q9UHD2 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
TBK1 | insertion | Frame_Shift_Ins | novel | c.1662_1663insTT | p.Leu555PhefsTer3 | p.L555Ffs*3 | Q9UHD2 | protein_coding | | | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
TBK1 | deletion | Frame_Shift_Del | novel | c.388delN | p.Gly130ValfsTer2 | p.G130Vfs*2 | Q9UHD2 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TBK1 | SNV | Missense_Mutation | novel | c.77N>A | p.Gly26Glu | p.G26E | Q9UHD2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
TBK1 | SNV | Missense_Mutation | novel | c.1478N>T | p.Ala493Val | p.A493V | Q9UHD2 | protein_coding | tolerated(0.3) | benign(0) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TBK1 | SNV | Missense_Mutation | | c.19N>T | p.His7Tyr | p.H7Y | Q9UHD2 | protein_coding | tolerated(1) | benign(0) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TBK1 | SNV | Missense_Mutation | | c.1738N>A | p.Glu580Lys | p.E580K | Q9UHD2 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TBK1 | SNV | Missense_Mutation | | c.177N>C | p.Leu59Phe | p.L59F | Q9UHD2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VS-A9UO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
29110 | TBK1 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME | | TAMATINIB | R-406 | |
29110 | TBK1 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME | | AZD-1775 | ADAVOSERTIB | |
29110 | TBK1 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME | | DNDI1417467 | CHEMBL1997335 | |
29110 | TBK1 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME | | Pyrimidinyl compound 6 | | |
29110 | TBK1 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME | | Pyrimidinyl compound 7 | | |
29110 | TBK1 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME | | Pyrimidinyl compound 1 | | |
29110 | TBK1 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME | | PF-562271 | PF-00562271 | |
29110 | TBK1 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME | inhibitor | 336446964 | | |
29110 | TBK1 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME | inhibitor | 336446965 | | |
29110 | TBK1 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME | | CYC-116 | CYC-116 | |